Systolic blood pressure at admission as a predictor of the response to initial carperitide therapy in patients hospitalized for acute decompensated heart failure with left ventricular systolic dysfunction

Cardiovascular Drugs and Therapy

Volumn 23, Issue 6, 2009, Pages 481-488

  Kajimoto, Katsuya ^a   Sashida, Yukiko ^a   Minami, Yuichiro ^a   Yumino, Dai ^a   Kawarai, Hirotaka ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute decompensated heart failure; Hemodynamics; Natriuretic peptide; Renal function; Systolic blood pressure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; ATRIAL NATRIURETIC FACTOR; NPPA PROTEIN, HUMAN;

ACUTE DECOMPENSATED HEART FAILURE; AGED; AREA UNDER THE CURVE; ARTICLE; CATHETERIZATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART RATE; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; BLOOD PRESSURE; CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; HOSPITAL ADMISSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; SEX DIFFERENCE; TIME;

AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; FEMALE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT ADMISSION; SEX FACTORS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77649219534     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6207-2     Document Type: Article

References (30)

1. Gheorghiade M, Zannad F, Sopko G, International Working Group on Acute Heart Failure Syndromes, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958-3968 (Pubitemid 43739494)
2. De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacological agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201-213
3. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol. 2005;96:5G-10G.
4. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36:S129-S39.
5. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G-7G.
6. Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2008. Published online ahead of print 19 December 2008
7. Lee CYW, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131-142
8. Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115-124
9. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Eng J Med. 2000;343:246-253
10. Publication Committee for the VMAC (Vasodilation in the management of acute CHF) Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540
11. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93:237-240
12. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005;69:283-290
13. Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure-COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008;72:1777-1786
14. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committe for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416
15. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:10-38.
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10:933-989
17. Sackner-Bernstein JD, Skopicke HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111:1487-1491
18. Sackner-Bernstein JD, Kawalski M, Fox M, Aaronson KD. Shortterm risk of death after treatment with nesiritide for decompensated heart failure. JAMA. 2005;293:1900-1905
19. Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant. 1999;18:1126-1132
20. Larsen AI, Gøransson L, Aarsland T, Tamby JF, Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J. 1997;134:435-441
21. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction. J Am Coll Cardiol. 2007;50:1835-1840
22. Serizawa T, Hirata Y, Kohmoto O, et al. Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn Heart J. 1988;29:143-149
23. Mizuno O, Onishi K, Dohi K, et al. Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure. Am J Cardiol. 2001;88:863-866
24. Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003;18:215-222
25. Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217-2226
26. Milo-Cotter O, Adams KF, O'Connor CM, et al. Acute heart failure associated with high admission blood pressure: a distinct vascular disorder? Eur J Heart Fail. 2007;9:178-183
27. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412
28. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 1994;266:R1244-50.
29. Hunt PJ, Espiner EA, Richards AM, Yandle TG, Frampton C, Nicholls MG. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am J Physiol. 1995;269:R1397-R403.
30. Kimura K, Yamaguchi Y, Horii M, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol. 2007;63:699-702.